

# Financial Tearsheet

## Company Overview

Dthera Sciences (OTCQB:DTHR), based in San Diego, Calif., is a digital therapeutics company focused on developing innovative quality of life therapies for the elderly and those suffering from cognitive decline. The Company's lead product, ReminX, is an artificial-intelligence-powered consumer health product designed to deliver reminiscence therapy digitally to individuals suffering from dementia from Alzheimer's disease and other neurodegenerative conditions, as well as for seniors experiencing social isolation. The company plans to launch ReminX commercially in the second quarter of 2018.

## Recent Financial News

Date	Headline
Apr 02, 2019	Dthera Sciences Announces Pursuit of Strategic Transaction
Feb 25, 2019	Dthera Sciences Announces Exclusivity Period and Option Agreement for its Digital Therapeutic in the Japanese Market
Feb 13, 2019	Dthera Sciences SVP to Speak on Keynote Panel about Digital Therapeutics in Biopharma at OCT West Coast Conference
Feb 06, 2019	Dthera Sciences CTO to Present on Digital Therapeutics for NASA at MIT Workshop on Cognitive Performance in Space
Jan 07, 2019	Dthera Sciences Chief Technology Officer to Speak at CES Digital Health Summit

## IR Contacts

### INVESTOR RELATIONS

Marek Ciszewski, J.D.  
 Managing Director, Head of Life Sciences  
 LIOLIOS  
 4685 MacArthur Court, Suite 400  
 Newport Beach, CA 92660  
 Tel: 949.574.3860  
 Email: [marek@liolios.com](mailto:marek@liolios.com)  
[www.liolios.com](http://www.liolios.com)

### TRANSFER AGENT

Interwest Transfer Co., Inc.  
 1981 Murray Holladay Road  
 Suite 100  
 Salt Lake City, UT 84117  
 Tel: 801-272-9294  
[www.interwesttc.com](http://www.interwesttc.com)

### AUDITORS

Sadler Gibb & Associates  
 Certified Public Accountants  
 2455 East Parleys Way  
 Suite 320  
 Salt Lake City, UT 84109  
 Tel: 801-783-2950  
<http://www.sadlergibb.com>

### CORPORATE COUNSEL

Salt Lake City  
 Kirton McConkie Building  
 50 East South Temple  
 Suite 400  
 Salt Lake City, UT 84111  
 Tel: 801-328-3600  
 Fax: 801-321-4893
















## Stock Performance

<b>Today's Open</b>	0.9000
<b>Volume</b>	1,000
<b>Day Range</b>	0.9000 - 0.9000
<b>52 Week Range</b>	0.3600 - 9.2500
<b>Bid/Ask</b>	0.6000 / 1.7400
<b>Bid/Ask Size</b>	1,000 X 700
<b>Previous Close</b>	0.8800
<b>Market Cap</b>	2.4 million
<b>Shares Outstanding</b>	2.67 million
<b>Dividend/Yield</b>	0.0000 / 0.0000%
<b>EPS (TTM)</b>	-1.435500
<b>P/E Ratio (TTM)</b>	N/A

Symbol: DTHR  
 Last Trade: \$0.60  
 Change (%): ↓ -1.14 (-65.52%)  
 Volume: 1000

06/17/2019 03:39 PM ET  
 Quotes delayed at least 20 mins.

## Recent XBRL Filings

Filing Date ▾	Form Type	Description	View
Nov 14, 2018	10-Q	Quarterly report	  
Aug 14, 2018	10-Q	Quarterly report	  
May 15, 2018	10-Q	Quarterly report	  
Apr 02, 2018	10-K	Annual report	  
Nov 14, 2017	10-Q	Quarterly report	  

**Management Team**

Edward Cox, CEO

Dave Keene, CTO

**Board of Directors**

Michael R. Feldschuh, Director

James A. Lombard, Director

Martin S. Wolpoff, Director

Edward S. Feuer, Director

Bernhard Saxe, Director

Jonathan Feldschuh, Chief Scientific Officer